Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
We are seeking to out-license our innovative Soluleaves range More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
rHu G-CSF More
A Robarts' Scientist has generated a target-based primary in vitro cell-based screen for evaluating compounds or peptides affecting scar matrix deposition and remodeling during wound repair. More
A suite of highly specific, proprietary bacterial drug targets in staphylococcus aureus, that can be used individually or as a group to develop small molecule or peptide drug leads with powerful anti-infectives properties. More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
Technology regarding new methods to efficiently and cost-effectively produce recombinant proteins from the milk of genetically-modified farm animals, applying methodologies of genetic engineering and transgenesis to pharmaceutical manufacturing. More
POL6326, a CXCR4 antagonist, currently in Phase I clinical studies More
Use of depth filters to remove prion infectivity from plasma - derived therapeutic products and/or other biologics. Depth Filtration is a chemically inactive process and therefore does not introduce potentially toxic bi-products or alter components. More
Naturally occurring compound shown to inhibit and reverse fatty liver. More
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Blood composition
- Blood disorders
- Blood substitute
- Blood Transfusion
- Fibrogenesis
- Hemorrhagic trauma
- Lymphatic disorders
- Sepsis
- Thrombosis
- Whole blood substitute
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us